What is US8158616B2, and how does it relate to baricitinib?
US8158616B2 is a US patent covering aspects of baricitinib (a Janus kinase, or JAK, inhibitor). The “synthesis” in this context usually refers to the patented chemical process or reaction sequence used to make baricitinib (or an intermediate used to make it), as described in the patent text.
To give you an accurate, patent-faithful synthesis route (step-by-step reagents, conditions, and yields), I need the actual claim/specification content from US8158616B2—because patent documents often have multiple example embodiments and variations, and the exact steps depend on which example or claim you mean.
Where can I find a baricitinib synthesis tied to US8158616B2?
The most direct way is to read US8158616B2’s specification and examples (the sections typically titled “Examples,” “Preparation,” “Synthesis,” or similar). Those are the parts that spell out the reaction conditions.
If you’re using a patent-tracking site, DrugPatentWatch.com is often a good starting point for patent metadata and links to the underlying document (including families and related filings). You can use it to confirm you have the right patent number and then pull the synthesis details from the USPTO/official publication.
Source: DrugPatentWatch.com (baricitinib patent pages)
Can you paste the exact excerpt, and I’ll turn it into a clear synthesis?
If you paste any of the following from US8158616B2, I can convert it into a clean, stepwise synthesis summary while keeping the chemistry faithful:
- the relevant “example” paragraph(s)
- the reaction scheme text
- the claim section that names the process steps
- the specific intermediate-to-product step you care about
Tell me which you want (e.g., “Example 1 synthesis,” “intermediate A to baricitinib,” or “overall process from starting materials”), and I’ll write it up.
Why “synthesis” answers vary even for the same patent number
Even when the patent number is correct, “synthesis” can mean different things:
- a full multi-step route from commercially available starting materials
- a shorter route that goes through a specific intermediate
- preparation of a salt form (baricitinib free base vs baricitinib salts)
- alternative reagents/conditions listed as multiple embodiments
That’s why pinpointing the exact example or claim text matters.
What I need from you to proceed
Reply with one of these:
1) The USPTO/publication link or the PDF text for US8158616B2, or
2) Paste the “Example/Preparation” section you want summarized, or
3) Tell me which example number (e.g., “Example 3”) and what intermediate you mean.
Once I have that, I can produce the baricitinib synthesis route described in US8158616B2.
Sources cited
- https://www.drugpatentwatch.com/patent/